Recent Investment Analysts’ Ratings Changes for RxSight (RXST)

Several analysts have recently updated their ratings and price targets for RxSight (NASDAQ: RXST):

• 9/22/2026 – RxSight had its price target lowered by Jefferies Financial Group Inc. from $6.50 to $5.75. They now have a “hold” rating on the stock.
• 9/22/2026 – RxSight had its price target lowered by Bank of America Corporation from $6.50 to $5.50. They now have an “underperform” rating on the stock.
• 9/20/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/12/2026 – RxSight was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/8/2026 – RxSight had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/29/2026 – RxSight was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/10/2026 – RxSight had its price target lowered by Stifel Nicolaus from $8.00 to $7.00. They now have a “hold” rating on the stock.
• 8/8/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/6/2026 – RxSight had its price target raised by UBS Group AG from $5.50 to $6.30. They now have a “neutral” rating on the stock.

Insider Buying and Selling at RxSight

In other news, CFO Mark Wilterding sold 7,765 shares of RxSight stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $54,044.40. Following the completion of the sale, the chief financial officer owned 25,049 shares of the company’s stock, valued at $174,341.04. The trade was a 23.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ronald M. Md Kurtz sold 5,100 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the transaction, the insider owned 71,775 shares in the company, valued at $499,554. This trade represents a 6.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,947 shares of company stock valued at $117,951 over the last quarter. 10.05% of the stock is currently owned by insiders.

RxSight, Inc is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to adjust a patient’s vision after surgery rather than relying solely on preoperative measurements and the initial implanted lens.

Its primary products include the RxSight Light Adjustable Lens and the RxSight Light Delivery Device. The lens is implanted during cataract surgery and can be adjusted after surgery through controlled ultraviolet-light treatments delivered by the company’s device.